Please login to the form below

Not currently logged in
Email:
Password:

New cancer meds and drug extensions top CHMP recommendations

Drugs for rare disease, oncology and diabetes top regulator’s endorsements
EU flag

Three new medicines and six licence extensions have all been recommended for European approval from the CHMP.

The CHMP, the drug safety and efficacy arm of the EMA, has recommended approval for Otsuka's Jinarc (tolvaptan) for the treatment of patients with autosomal dominant polycystic kidney disease (ADPKD), and Sanofi's new insulin Toujeo, the follow up to its blockbuster insulin Lantus.

The CHMP has also recommended granting a conditional marketing authorisation for Novartis' Zykadia (ceritinib).

Specifically, the licence for the drug is for non-small cell lung cancer patients expressing the anaplastic lymphoma kinase (ALK) mutation.

It is designed to treat patients at an advanced stage and in a second-line setting, after patients have already been treated with Pfizer's established ALK lung cancer treatment Xalkori (crizotinib).

The CHMP also made six recommendations on extensions of therapeutic indication.

This includes Adenuric, blockbuster oncology treatment Avastin (bevacizumab) from Roche; AbbVie's auto-inflammatory drug Humira (adalimumab), Menarini's gout drug Adenuric, (febuxostat), the rare disease drug for kidney disease Soliris (eculizumab), BMS's HIV pill Sustiva (efavirenz), and finally Amgen's cancer medicine Vectibix (panitumumab).

Article by
Ben Adams

3rd March 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics